Di Raimondo F, LaPushin R, Hersh E M
Chair of Medical Semeiotics and Hematology, University of Catania, Italy.
Acta Haematol. 1987;78 Suppl 1:77-83. doi: 10.1159/000205908.
The effects of a combination of recombinant alpha-interferon (IFN-alpha) and interleukin-2 (IL-2)-activated human killer cells (lymphokine-activated killer or LAK cells) on Hs294T (IFN-sensitive) and A375P (IFN-resistant) human melanoma cell lines were evaluated. Pretreatment of target cells with IFN-alpha for at least 1 day increased their susceptibility to the lytic activity of LAK cells. The combination of the two agents in sequence (IFN-alpha followed by LAK cells) resulted in a true synergystic killing of both IFN-alpha-sensitive and resistant tumor cells. No synergy was observed when the sequence was reversed (LAK cells followed by IFN-alpha). When peripheral blood mononuclear cells were incubated simultaneously with IFN-alpha and IL-2, LAK cell generation and antitumor activity was markedly inhibited when tested against both IFN-treated and -non-treated tumor cells. These studies may be used to plan clinical trials of combination cytokine therapy for human cancer.
评估了重组α干扰素（IFN-α）与白细胞介素-2（IL-2）激活的人杀伤细胞（淋巴因子激活的杀伤细胞或LAK细胞）联合使用对Hs294T（IFN敏感）和A375P（IFN耐药）人黑色素瘤细胞系的影响。用IFN-α预处理靶细胞至少1天可增加其对LAK细胞裂解活性的敏感性。两种药物按顺序联合使用（IFN-α后接LAK细胞）可对IFN-α敏感和耐药的肿瘤细胞产生真正的协同杀伤作用。当顺序颠倒时（LAK细胞后接IFN-α）未观察到协同作用。当外周血单个核细胞与IFN-α和IL-2同时孵育时，针对IFN处理和未处理的肿瘤细胞进行测试时，LAK细胞的生成和抗肿瘤活性均受到明显抑制。这些研究可用于规划人类癌症细胞因子联合治疗的临床试验。
